Company intelligence / Profile preview

Cancer Vaccines

Carlsbad, California, United States

Ownership: Private
Development stage: Other

Overview

CancerVax was a biotechnology company focused on the research, development, and commercialization of novel biological products for the treatment and control of cancer. The company's lead product candidate, Canvaxin, was a whole-cell therapeutic vaccine intended for the treatment of late-stage melanoma, though it ultimately failed in Phase 3 clinical trials. Following the clinical failure of its lead program, the company underwent a strategic shift and was eventually acquired by Micromet in 2006. The company's legacy is primarily associated with early efforts in the cancer immunotherapy and therapeutic vaccine space.

Therapeutic areas: Oncology
Modalities: VaccineMonoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Cancer Vaccines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cancer Vaccines.

Explore the full profile